TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time in the therapeutic range (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualised consumption of pain medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Annualised consumption of anti-anxiety medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Annualised consumption of anti-depressive medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients receiving intermittent therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of participants maintaining CR/PR off therapy for at least 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in driving scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of subjects requiring secondary surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: New Diagnosis of Low Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spinal cord injury severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pupillary Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive circumferential margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement of dyspareunia severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Trough Sitting Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS Negative/positive feeling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Relief of gastrointestinal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relief of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in time spent inactive
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Hematocrit level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum tolerated dose (MTD)/RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Intraocular Pressure (IOP) at 9 AM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP At 4 PM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultrasound volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: imaging strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tonometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-Lens Non-Invasive Keratograph Break Up Time (PL NIK-BUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of All Laboratory-confirmed Symptomatic Dengue Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Overbite correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain after builds-up placement
Endpoint domain: Adverse events/effects
Primary endpoint: Oral Health Impact Profile after builds-up placement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Experiencing Grade 3-4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Symptomatic recurrent PE/DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: NAPSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD Events
Endpoint domain: Mortality/survival
Primary endpoint: Sleep Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Epidermal Barrier Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative Sodium Excretion (Natriuresis) at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal improvement in visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total-PSA (tPSA) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the f/tPSA Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IGF-I Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-inflammatory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-needling soreness intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin response to glucose changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Responder to Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proper Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Adequacy of Ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Tlast (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration of Tirzepatide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal peak torque of the knee extensors muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Achieving CAPS Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulp vitality maintenance diagnosed by clinical exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulp vitality maintenance diagnosed by radiograph exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fasting blood glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distinction between bacterial and viral pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Incontinent Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Kidney Event (MAKE)
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural Activation Patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of Renal Function (SCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral Measures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of aggravated inflammatory signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of STIs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Therapeutic failure (intubation or death)
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in Self-Compassion Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Pain Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Development of neonatal hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rates of Kras, Braf, or PI3K tumor DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Disability Assessment for Dementia (DAD) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of biomarkers of antitumor activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: new root caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complexity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Protraction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain measured using the WOMAC pain sub-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strengths and Difficulties Questionnaire Total Difficulties Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MacArthur-Bates Communicative Development Inventory (100 word Danish version)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of HIV-1 uninfected partners staying HIV-1 uninfected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence of AF or AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortisol Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Perceived happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Impact of hypoglycemia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in peak systolic strain rate (SRSYS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endometriosis Health Profile 30® (EHP-30®)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Total Tic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS pain during mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine-eqv. opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: muscle sympathetic nerve activity (MSNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp Score (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Minutes of activity added in school day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intervention effects on psychosocial determinants
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intervention effects on self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of patients with the intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Plasma Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with Deficiency in Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Global Satisfaction with Sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Clinical Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change of Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change of Visual-motor integration in Peabody-Developmental Motor Scales (PDMSⅡ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of grasping in Peabody-Developmental Motor Scales (PDMSⅡ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Chinese Version of Pediatric Evaluation of Disability Inventory (PEDI-C)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of GAS (goal attainment scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetics of capecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Seroconversion rates of polio virus (type 1 and type 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number (%) of patients with clinical benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Blame explicit bias
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients treated with Allogeneic stem cell transplantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Berger Space larger than 400μm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic arterial elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified-Aldrete Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ricker's Agitation Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hepatic function parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical alleviation of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in soluble intercellular adhesion molecule level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically-validated smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' satisfaction with the treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventricular evoked response signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Demonstrated Acute Adverse Events Following Infusion
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of cases that develop severe pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Device related adverse event up to 1 month follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Successful closure/procedure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Regional Wall Abnormalities Identified on Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum concentration (Cmax) of DS-8500a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of maximum concentration (Tmax) of DS-8500a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration curve (AUC) of DS-8500a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in One(1) Mile Timed Run
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FSH (Follicle stimulating hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LH (luteinizing hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Estrogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in the TTS of the YGTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse serious unexpected reactions attributable to the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Complications in the place of the infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Appearance of a new neurological effect not attributable to the natural progression of this pathology
Endpoint domain: Adverse events/effects
Primary endpoint: Theory of Mind performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to TOF-ratio 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Work-metabolic Index (WMI) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Perfusion Reserve Index (MPRI) by Magnetic Resonance Imaging at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Myocardial Fibrosis (T1 Time) by Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ADP-Induced P2Y12 Receptor-Mediated Platelet Aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SCORing Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Patient Oriented Eczema Measure (POEM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nottingham Eczema Severity Score (NESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early embryonic death
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline oxygen uptake at 48 hours after the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline stride length at 48 hours after the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline rating of perceived exertion at 48 hours after the treatment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prostate biopsy length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Prior 2-Month Indoor Tanning Sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients by Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fistula drainage volume > 50% of baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of opioid analgesics used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in visual acuity (Snellen scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in visual acuity (Parinaud scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in serum level of insulin and lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Void Trial Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensibility of the eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of size-appropriate restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger and foot tapping speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inflammatory marker (high sensitive C-reactive protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oxidative stress marker (homocysteine, cysteine and paraoxonase-1 activity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiotensin converting enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistence with aripiprazole once-monthly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed bleeding rate after ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Response at Test-of-cure Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes